AbbVie's Post-Humira Growth Story Has One Question Mark

AbbVie (ABBV) is executing well on its post-Humira plan, but a recent analysis from Trefis highlights one question mark: a slight deceleration in the growth rate of one of its two key drugs, Skyrizi or Rinvoq.

The Strategy

AbbVie has relied on Skyrizi (for psoriasis and psoriatic arthritis) and Rinvoq (for rheumatoid arthritis and other conditions) to offset declining Humira sales. Both drugs have exceeded expectations.

The Question Mark

The analysis notes that the growth rate of one of these two drugs has slowed modestly in recent quarters. While the slowdown is small, it could impact long-term projections if it persists.

Context

Despite this, analysts remain broadly positive on AbbVie due to its strong pipeline and diversified portfolio. The company is also advancing treatments in oncology and neuroscience.

What It Means for Investors

Investors should monitor the growth trajectories of Skyrizi and Rinvoq in upcoming earnings reports. A continued slowdown may warrant a reassessment, but the current strategy still appears successful.